Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Multiple sclerosis: effect of beta interferon treatment on survival.

Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H.

Brain. 2019 May 1;142(5):1324-1333. doi: 10.1093/brain/awz055.

2.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
3.

Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.

Palace J, Duddy M, Lawton M, Bregenzer T, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Lilford R, Dobson C.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):251-260. doi: 10.1136/jnnp-2018-318360. Epub 2018 Sep 21.

4.

Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.

Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM; IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators.

Mult Scler. 2019 May;25(6):837-847. doi: 10.1177/1352458518773511. Epub 2018 May 15.

PMID:
29761737
5.

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.

Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

Health Technol Assess. 2016 Oct;20(81):1-48.

6.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

7.

Disability progression in aggressive multiple sclerosis.

Menon S, Zhu F, Shirani A, Oger J, Freedman MS, Tremlett H.

Mult Scler. 2017 Mar;23(3):456-463. doi: 10.1177/1352458516653273. Epub 2016 Jul 11.

PMID:
27325603
8.

Association between the use of selective serotonin reuptake inhibitors and multiple sclerosis disability progression.

Zhang T, Kingwell E, De Jong HJ, Zhu F, Zhao Y, Carruthers R, Petkau J, Gustafson P, Oger J, Tremlett H.

Pharmacoepidemiol Drug Saf. 2016 Oct;25(10):1150-1159. doi: 10.1002/pds.4031. Epub 2016 May 23.

PMID:
27211481
9.

Treatment of Myasthenia Gravis in the Aged.

Alkhawajah NM, Oger J.

Drugs Aging. 2015 Sep;32(9):689-97. doi: 10.1007/s40266-015-0297-2. Review.

PMID:
26363907
10.

An update on laboratory diagnosis in myasthenia gravis.

Oger J, Frykman H.

Clin Chim Acta. 2015 Sep 20;449:43-8. doi: 10.1016/j.cca.2015.07.030. Epub 2015 Aug 1. Review.

PMID:
26238187
11.

Amyotrophic lateral sclerosis presentation of a human T-lymphotropic virus type-1 myelopathy--insight into pathogenesis.

Alkhawajah NM, Chapman KM, Moore GR, Oger J.

APMIS. 2015 Sep;123(9):815-20. doi: 10.1111/apm.12422. Epub 2015 Jul 30.

PMID:
26224593
12.

A longitudinal model for disease progression was developed and applied to multiple sclerosis.

Lawton M, Tilling K, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.

J Clin Epidemiol. 2015 Nov;68(11):1355-65. doi: 10.1016/j.jclinepi.2015.05.003. Epub 2015 May 14.

13.

Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years.

MacMillan EL, Tam R, Zhao Y, Vavasour IM, Li DK, Oger J, Freedman MS, Kolind SH, Traboulsee AL.

Mult Scler. 2016 Jan;22(1):112-6. doi: 10.1177/1352458515586086. Epub 2015 May 26.

PMID:
26014604
14.

Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.

Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H.

Biomed Res Int. 2015;2015:451912. doi: 10.1155/2015/451912. Epub 2015 Apr 1.

15.

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis.

Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M.

Mult Scler Relat Disord. 2014 May;3(3):294-302. doi: 10.1016/j.msard.2013.11.005. Epub 2013 Nov 26. Review.

PMID:
25876467
16.

Beta-interferon exposure and onset of secondary progressive multiple sclerosis.

Zhang T, Shirani A, Zhao Y, Karim ME, Gustafson P, Petkau J, Evans C, Kingwell E, van der Kop M, Zhu F, Oger J, Tremlett H; BC MS Clinic Neurologists.

Eur J Neurol. 2015 Jun;22(6):990-1000. doi: 10.1111/ene.12698. Epub 2015 Apr 6.

17.

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.

Palace J, Duddy M, Bregenzer T, Lawton M, Zhu F, Boggild M, Piske B, Robertson NP, Oger J, Tremlett H, Tilling K, Ben-Shlomo Y, Dobson C.

Lancet Neurol. 2015 May;14(5):497-505. doi: 10.1016/S1474-4422(15)00018-6. Epub 2015 Apr 1.

PMID:
25841667
18.

Serum proteomics in multiple sclerosis disease progression.

Tremlett H, Dai DL, Hollander Z, Kapanen A, Aziz T, Wilson-McManus JE, Tebbutt SJ, Borchers CH, Oger J, Cohen Freue GV.

J Proteomics. 2015 Apr 6;118:2-11. doi: 10.1016/j.jprot.2015.02.018. Epub 2015 Mar 6.

PMID:
25753122
19.

An update on laboratory diagnosis in myasthenia gravis.

Oger J, Frykman H.

Clin Chim Acta. 2015 Apr 15;444:126-31. doi: 10.1016/j.cca.2015.01.042. Epub 2015 Feb 15. Review.

PMID:
25689792
20.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

21.

Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs.

Gibbs E, Karim ME, Oger J; Steering Committee of the BENEFIT study.

Clin Immunol. 2015 Mar;157(1):91-101. doi: 10.1016/j.clim.2014.12.005. Epub 2014 Dec 24.

PMID:
25543089
22.

Association between beta-interferon exposure and hospital events in multiple sclerosis.

Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H.

Pharmacoepidemiol Drug Saf. 2014 Nov;23(11):1213-22. doi: 10.1002/pds.3667. Epub 2014 Jun 21.

PMID:
24953054
23.

Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort.

Karim ME, Gustafson P, Petkau J, Zhao Y, Shirani A, Kingwell E, Evans C, van der Kop M, Oger J, Tremlett H.

Am J Epidemiol. 2014 Jul 15;180(2):160-71. doi: 10.1093/aje/kwu125. Epub 2014 Jun 17.

24.

Assessment of cancer risk with β-interferon treatment for multiple sclerosis.

Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1096-102. doi: 10.1136/jnnp-2013-307238. Epub 2014 Mar 4.

PMID:
24594506
25.

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, Duddy M, Dobson C.

BMJ Open. 2014 Jan 17;4(1):e004073. doi: 10.1136/bmjopen-2013-004073. Erratum in: BMJ Open. 2014;4(1):e004073corr1. Zhu, Fheng [corrected to Zhu, Feng].

26.

Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.

Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H.

Eur J Neurol. 2014 Jun;21(6):835-44. doi: 10.1111/ene.12324. Epub 2013 Dec 18.

PMID:
24351059
27.

Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing.

Alkhawajah NM, Oger J.

Muscle Nerve. 2013 Nov;48(5):705-10. doi: 10.1002/mus.23964. Review.

PMID:
23893883
28.

Somatostatin preserved blood brain barrier against cytokine induced alterations: possible role in multiple sclerosis.

Basivireddy J, Somvanshi RK, Romero IA, Weksler BB, Couraud PO, Oger J, Kumar U.

Biochem Pharmacol. 2013 Aug 15;86(4):497-507. doi: 10.1016/j.bcp.2013.06.001. Epub 2013 Jun 13.

PMID:
23770458
29.

Characterising aggressive multiple sclerosis.

Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman MS, Tremlett H.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1192-8. doi: 10.1136/jnnp-2013-304951. Epub 2013 Jun 6.

PMID:
23744892
30.

Interferon beta and long-term disability in multiple sclerosis.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.

JAMA Neurol. 2013 May;70(5):651-2. doi: 10.1001/jamaneurol.2013.2197. No abstract available.

PMID:
23699948
31.

DMDs are an essential issue but are they the only issue in MS treatment?

Shahbeigi S, Oger J.

Can J Neurol Sci. 2013 May;40(3):276-7. No abstract available.

PMID:
23603158
32.

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories.

Shahkarami MA, Vaziri B, Salami S, Harandi AA, Oger J.

J Immunol Methods. 2013 Feb 28;388(1-2):46-8. doi: 10.1016/j.jim.2012.11.013. Epub 2012 Dec 6.

PMID:
23220098
33.

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V.

BMJ Open. 2012 Nov 30;2(6). pii: e001972. doi: 10.1136/bmjopen-2012-001972. Print 2012.

34.

Hospital admissions and MS: temporal trends and patient characteristics.

Evans C, Kingwell E, Zhu F, Oger J, Zhao Y, Tremlett H.

Am J Manag Care. 2012 Nov;18(11):735-42.

35.

Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know!

Alkhawajah MM, Caminero AB, Freeman HJ, Oger JJ.

Mult Scler. 2013 Mar;19(3):259-65. doi: 10.1177/1352458512461393. Epub 2012 Oct 1. Review.

PMID:
23027881
36.

Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.

Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H.

Mult Scler. 2013 Apr;19(5):577-84. doi: 10.1177/1352458512459684. Epub 2012 Sep 7.

PMID:
22961214
37.

Insights into origins of Human T-cell Lymphotropic Virus Type 1 based on new strains from aboriginal people of Canada.

Andonov A, Coulthart MB, Pérez-Losada M, Crandall KA, Posada D, Padmore R, Giulivi A, Oger JJ, Peters AA, Dekaban GA.

Infect Genet Evol. 2012 Dec;12(8):1822-30. doi: 10.1016/j.meegid.2012.07.015. Epub 2012 Aug 13.

PMID:
22921499
38.

'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study.

Leray E, Coustans M, Le Page E, Yaouanq J, Oger J, Edan G.

Mult Scler. 2013 Apr;19(4):458-65. doi: 10.1177/1352458512456613. Epub 2012 Aug 2.

PMID:
22859724
39.

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.

Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.

JAMA. 2012 Jul 18;308(3):247-56. doi: 10.1001/jama.2012.7625.

PMID:
22797642
40.

Natural, innate improvements in multiple sclerosis disability.

Tremlett H, Zhu F, Petkau J, Oger J, Zhao Y; BC MS Clinic Neurologists.

Mult Scler. 2012 Oct;18(10):1412-21. Epub 2012 Jun 26.

PMID:
22736751
41.

Cancer risk in multiple sclerosis: findings from British Columbia, Canada.

Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H.

Brain. 2012 Oct;135(Pt 10):2973-9. doi: 10.1093/brain/aws148. Epub 2012 Jun 21.

PMID:
22730559
42.

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V.

Neurology. 2012 Apr 24;78(17):1315-22. doi: 10.1212/WNL.0b013e3182535cf6. Epub 2012 Apr 11.

43.

Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.

Evans C, Tam J, Kingwell E, Oger J; University of British Columbia MS Clinic Neurologists, Tremlett H.

Clin Ther. 2012 Feb;34(2):341-50. doi: 10.1016/j.clinthera.2012.01.006. Epub 2012 Jan 31.

PMID:
22296946
44.

When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?

Alkhawajah M, Oger J.

Mult Scler Int. 2011;2011:724871. doi: 10.1155/2011/724871. Epub 2011 May 17.

45.

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.

Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Li D, Hartung HP, Krantz M, Ferenczi L, Verco T; MAESTRO-01 Investigators.

Neurology. 2011 Oct 18;77(16):1551-60. doi: 10.1212/WNL.0b013e318233b240. Epub 2011 Oct 5.

PMID:
21975206
46.

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada.

Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H.

J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):61-6. doi: 10.1136/jnnp-2011-300616. Epub 2011 Aug 23.

PMID:
21865212
47.

Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada.

Pakzad Z, Aziz T, Oger J.

Neurology. 2011 Apr 26;76(17):1526-8. doi: 10.1212/WNL.0b013e318217e735. No abstract available.

PMID:
21519005
48.

Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.

Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.

J Interferon Cytokine Res. 2011 Mar;31(3):337-44. doi: 10.1089/jir.2010.0038. Epub 2011 Jan 12.

PMID:
21226608
49.

High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study.

Chan S, Kingwell E, Oger J, Yoshida E, Tremlett H.

Mult Scler. 2011 Mar;17(3):361-7. doi: 10.1177/1352458510388823. Epub 2010 Dec 10.

PMID:
21148660
50.

CCSVI: hope, hype or snake oil?

Oger J, Alkhawajah M.

Can J Neurol Sci. 2010 Nov;37(6):716. No abstract available. Erratum in: Can J Neurol Sci. 2011 Mar;38(2):379. Alkhajawah, Mona [corrected to Alkhawajah, Mona].

PMID:
21059529

Supplemental Content

Support Center